Development, Standardisation and Standardisation Project for a New Memory Assessment (NEM)

April 29, 2026 updated by: University Hospital, Tours
Episodic memory (EM) is a neuropsychological marker of Alzheimer's disease (AD) (Thomas-Anterion, 2006). Current tests for its assessment do not take into account the identity and emotional aspects of memory (Van der Linden et al., 2018). However, there are models that integrate links with identity, self-awareness and experience. Pause et al. (2013) propose criteria to create ecological tools, including consideration of the emotional valence of memories and the spatio-temporal context of acquisition. In line with these criteria, we have developed a new tool: the NEM (New evaluation of Episodic Memory). Preliminary studies show different response profiles on the NEM among patients (Launay et al., 2023). We now want to evaluate the relevance of this tool in the differential diagnosis of AD.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Tours, France, 37044
        • Recruiting
        • University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patient attending a memory consultation for suspected Alzheimer's disease.

Description

Inclusion Criteria:

  • Age ≥ 50 years
  • Ability to understand judged sufficient by the assessor;
  • Amnesic MCI profile (Petersen, 2003) during the 1st medical consultation prior to the assessment being prescribed.

Exclusion Criteria:

  • Severe auditory and/or visual sensory impairment not compatible with neuropsychological assessment;
  • Judged fit to take the test by the assessor;
  • Patient under guardianship, curatorship or family guardianship;
  • Opposition to data processing.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
group intervention
patients benefiting from the new memory assessment
Other: New memory assessment
The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Score total NEM (new memory assessment)
Time Frame: baseline
Sum of the episodic elements
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NEM sub-scores
Time Frame: baseline
Sum of the episodic elements by category
baseline
Total RL/RI 16 Recall
Time Frame: baseline
(Van der Linden et al., 2014)
baseline
Delayed Mem Logic Recall
Time Frame: baseline
(MEM IV, Wechsler, 2014)
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Tours

Investigators

  • Principal Investigator: Alix LAUNAY, Tours University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 22, 2024

Primary Completion (Estimated)

November 1, 2028

Study Completion (Estimated)

November 1, 2028

Study Registration Dates

First Submitted

August 19, 2024

First Submitted That Met QC Criteria

August 19, 2024

First Posted (Actual)

August 21, 2024

Study Record Updates

Last Update Posted (Actual)

April 30, 2026

Last Update Submitted That Met QC Criteria

April 29, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DR240067-NEM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Memory Disorders

Clinical Trials on New memory assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe